Retinoblastoma – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030
Retinoblastoma is a rare tumor but is childhood’s most common eye tumor. Retinoblastoma is a malignant tumor of the developing retina that occurs in children, usually before age five years. Retinoblastoma develops from cells that have cancer-predisposing variants in both copies of RB1. Retinoblastoma may be unifocal or multifocal. About 60% of affected individuals have unilateral retinoblastoma with a mean age of diagnosis of 24 months; about 40% have bilateral retinoblastoma with a mean age of diagnosis of 15 months. Heritable retinoblastoma is an autosomal dominant susceptibility for retinoblastoma. Individuals with heritable retinoblastoma are also at increased risk of developing non-ocular tumors. The prognosis is excellent for long-term survival when it remains localized to the eye, whereas metastatic retinoblastoma is an aggressive malignant neoplasm with poor survival rates. Through this experience, retinoblastoma has been found to have a vital genetic component. Some cases, especially those with both eyes, have exhibited an autosomal dominant inheritance pattern. The treatment of retinoblastoma is multidisciplinary aims at saving lives and preserving vision. The intraocular disease is highly curable. More than 90% of patients survive.
The
average age-adjusted incidence rate of retinoblastoma in the United States
varies between 1 to 1.25 cases in 15,000 live births, with a 97% to 99%
survival rate.
The
competitive landscape includes country-specific approved and pipeline
therapies. Any asset/product-specific designation or review and Accelerated
Approval are tracked and supplemented with analyst commentary.
KOLs insights of Retinoblastoma
across 8 MM market from the center of Excellence/ Public/ Private hospitals
participated in the study. Insights around current treatment landscape,
epidemiology, clinical characteristics, future treatment paradigm, and Unmet
needs.
Retinoblastoma
Market Forecast:
Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data
Inputs with sourcing, Market Event, and Product Event, Country specific
Forecast Model, Market uptake and patient share uptake, Attribute Analysis,
Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
S. No Asset Company Stage
1 Conbercept ophthalmic injection Chengdu Kanghong Biotech Co., Ltd. Phase
2
2 Episcleral Topotecan Targeted
Therapy Technologies, LLC Phase
1
3 VCN-01 VCN Biosciences,
S.L. Phase 1/2
Comments
Post a Comment